AI Science Tracker
EN

The Affiliated People’s Hospital of Jiangsu University

1 discovery from 2026

Discoveries

Machine Learning-Based Prediction of Disease-Free Survival in Breast Cancer Incorporating Clinical and Treatment Information: Retrospective Cohort Study With External Validation.

Source check: Source checked. Not independent scientific confirmation.

Finding: An XGBoost accelerated-failure-time model combined clinical, pathological and treatment information to predict postoperative disease-free survival. It was developed on 861 patients, internally validated on 370 patients and externally evaluated on 304 TCGA patients; this retrospective validation does not establish clinical benefit.

Technology: XGBoost accelerated failure-time model; SHAP interpretation

Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.

AI contribution
XGBoost accelerated failure-time model; SHAP interpretation
Test and result
The reported 5-year AUC was 0.840 in training, 0.822 in internal validation and 0.762 in the TCGA external cohort; external concordance index was 0.750.
Limitation / still unknown
Both cohorts were retrospective; external validation does not establish prospective clinical utility or benefit.
Evidence sources and annotation context

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

Evidence sources: https://pubmed.ncbi.nlm.nih.gov/43024943/

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: paper. Paper: linked separately.

Review date: 22 Nov 2026. Review scope: Primary result-bearing material for the stated method, result and evaluation, with bibliographic version information..

No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.

Editorial assessment: Impact 3/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Open the interactive profile for the timeline, or browse all organizations and model families.